Celastrol-loaded ginsenoside Rg3 liposomes boost immunotherapy by remodeling obesity-related immunosuppressive tumor microenvironment in melanoma
Obesity usually exacerbates the immunosuppressive tumor microenvironment (ITME), hindering CD8<sup>+</sup> T cell infiltration and function, which further represents a significant barrier to the efficacy of immunotherapy. Herein, a multifunctional liposomal system (CR-Lip) for encapsulating celastrol (CEL) was utilized to remodel obesity-related ITME and improve cancer immunotherapy, wherein Ginsenoside Rg3 (Rg3) was detected interspersed in the phospholipid bilayer and its glycosyl exposed on the surface of the liposome. CR-Lip had a relatively uniform size (116.5 nm), facilitating favorable tumor tissue accumulation through the interaction between Rg3 and glucose transporter 1 overexpressed in obese tumor cells. Upon reaching the tumor region, CR-Lip was found to induce the immunogenic cell death (ICD) of HFD tumor cells. Notably, the level of PHD3 in HFD tumor cells was effectively boosted by CR-Lip to effectively block metabolic reprogramming and increase the availability of major free fatty acids fuel sources. <i>In vivo</i>, experiments studies revealed that the easy-obtained nano platform stimulated enhanced the production of various cytokines in tumor tissues, DC maturation, CD8<sup>+</sup> T-cell infiltration, and synergistic anticancer therapeutic potency with aPD-1 (tumor inhibition rate = 82.1%) towards obesity-related melanoma. Consequently, this study presented an efficacious approach to tumor immunotherapy in obese mice by encompassing tumor eradication, inducing ICD, and reprogramming metabolism. Furthermore, it offered a unique insight into a valuable attempt at the immunotherapy of obesity-associated related tumors.
Authors
- Yang Xiong (ORCID: https://orcid.org/0000-0002-9508-1987)
- Chaofeng Mu (ORCID: https://orcid.org/0000-0002-0655-1626)
- Donghang Xu (ORCID: https://orcid.org/0000-0001-5502-426X)
- Limei Shen (ORCID: https://orcid.org/0000-0002-7449-423X)
- Ninghui Ma
- Jingyi Huang (ORCID: https://orcid.org/0000-0001-5590-8954)
- Hongyan Zhang (ORCID: https://orcid.org/0000-0001-6424-3261)
- Mancang Gu (ORCID: https://orcid.org/0000-0003-3782-0988)
- Yujie Li (ORCID: https://orcid.org/0009-0006-1553-6141)
- Jiale Wei (ORCID: https://orcid.org/0009-0008-3274-4668)
- Wanyu Jin
Institutions
- University of North Carolina at Chapel Hill (US)
- Zhejiang Chinese Medical University (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
Publication Details
- Journal
- Acta Pharmaceutica Sinica B
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1016/j.apsb.2025.03.017
- Citations
- 9
- Primary Topic
- Natural Compounds in Disease Treatment
- Type
- article
- Field-Weighted Citation Impact
- 21.43